Recent Updates
Recently added Catalysts

VVD-133214

Phase 2

Colorectal Adenocarcinoma | Small molecule | Other |Bayer AG|Last Updated: Sep 9, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment140

FDA Designations

No designations recorded

Clinical trial landscape

VVD-133214 · 1 trial · 1 indication

Phase 2 1
NCT07811193A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or RectumColorectal Adenocarcinoma
NOT YET_RECRUITING140 Analytics
PHASE2NOT YET_RECRUITING
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Colorectal Adenocarcinoma
NCT07811193140
Unlock trial analytics

Study Endpoints

Primary Endpoints

Landmark progression-free survival (PFS) rate at 6 months, as assessed by the investigator
From start of study treatment until end of follow-up (up to approximately 36 months)

Defined as the proportion of participants who are alive and free from disease progression as per RECIST v1.1

Secondary Endpoints

Incidence and severity of Adverse Events (AEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)
From start of study treatment up to 30 days following the last dose of study drug (100 days after last administration of pembrolizumab)
Recommended Phase 2 Dose (RP2D) of VVD-133214 in combination with pembrolizumab
From start of study treatment until end of follow-up (up to approximately 36 months)
Maximum plasma concentration observed (Cmax) following single and multiple doses of VVD-133214
Predose and multiple timepoints post-dose, up to approximately 36 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
VVD-133214 Dose 1 + PembrolizumabEXPERIMENTALParticipants will receive VVD-133214 in combination with pembrolizumab
VVD-133214 Dose 2 + PembrolizumabEXPERIMENTALParticipants will receive VVD-133214 in combination with pembrolizumab
PembrolizumabACTIVE_COMPARATORParticipants will receive pembrolizumab only (monotherapy)

Interventions

NameTypeDescription
VVD-133214DRUGVVD-133214 will be administered orally
PembrolizumabDRUGPembrolizumab will be administered by intravenous infusion (IV) every three weeks
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites121

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 * Have a known microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) tumor status confirmed per local standard of care (SoC), and have histologically or cytologically documented adv...

Countries:United StatesArgentinaBelgiumBrazilChinaFranceGermanyGreeceHong KongItalyMalaysiaMexicoNetherlandsPolandPortugalSingaporeSouth KoreaSpainTaiwanTurkey (Türkiye)United Kingdom
Unlock Eligibility Criteria